Can a Fatty Liver Make You Nauseous?

Fatty liver disease can make you nauseous, particularly as the condition progresses beyond its earliest, often symptom-free stage. Medically known as hepatic steatosis or metabolic dysfunction-associated steatotic liver disease (MASLD), this condition occurs when excess fat builds up within liver cells, disrupting normal digestive and metabolic functions. Because the liver is central to bile production, nutrient processing and toxin clearance, its impairment can trigger nausea, upper abdominal discomfort and fatigue. This article explains why fatty liver causes these symptoms, when to seek medical advice, and how NHS diagnosis and lifestyle changes can help.

Can a fatty liver really cause nausea and an upset stomach?

Yes, fatty liver disease can cause nausea and digestive discomfort, especially as fat accumulation increases or inflammation develops, disrupting the liver's role in bile production and nutrient processing.

Yes, fatty liver disease can cause nausea and general digestive discomfort, particularly as the condition progresses beyond its earliest stage. Fatty liver disease, known medically as hepatic steatosis, occurs when excess fat accumulates within liver cells. The broader condition is now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), a term that has replaced non-alcoholic fatty liver disease (NAFLD) in international consensus; however, NICE guidance (NG49) and many NHS materials continue to use NAFLD, so both terms are used here. The liver sits in the upper right abdomen and plays a central role in digestion, bile production and the processing of nutrients, so when its function is disrupted, gastrointestinal symptoms may follow.

In the early stages, many people with fatty liver disease have no symptoms at all, which is why the condition is often discovered incidentally during blood tests or an ultrasound scan arranged for another reason.^[1][14] The NHS notes that NAFLD is frequently detected this way. However, as fat accumulation increases or inflammation develops, a proportion of people report nausea, a feeling of fullness after small meals, and a dull ache or heaviness in the upper right abdomen.

It is important to note that nausea is a non-specific symptom with many possible causes, ranging from dietary habits and medication side effects to other gastrointestinal conditions. Fatty liver disease is therefore rarely the first diagnosis considered when nausea is the only complaint. That said, if nausea persists alongside other features described below, it is worth discussing with a GP, who can arrange appropriate investigations to identify or rule out liver involvement.

What other symptoms tend to appear alongside nausea in fatty liver disease?

Fatigue, upper right abdominal pain, loss of appetite and bloating commonly accompany nausea; jaundice, dark urine and ascites indicate advanced disease requiring prompt assessment.

Fatty liver disease is often associated with a cluster of symptoms beyond nausea, including persistent fatigue, upper right abdominal discomfort, and a general sense of feeling unwell. Fatigue is one of the most commonly reported complaints and can be significant enough to affect daily functioning, even when liver enzyme levels are only mildly elevated.

Other symptoms that may accompany nausea include:

• Upper right abdominal pain or heaviness, which may be related to an enlarged liver or to coexisting conditions such as gallstone disease

• Loss of appetite, which can contribute to unintentional weight loss in more advanced cases and warrants prompt assessment

• Bloating and indigestion, which may reflect the liver's reduced efficiency in processing fats and producing bile, or may arise from coexisting conditions such as gastro-oesophageal reflux disease (GORD)

• Difficulty concentrating, which some patients report; this is a patient-reported feature rather than a core diagnostic symptom, and its mechanism is not fully established

In more advanced liver disease, such as metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) or cirrhosis, additional signs may emerge. These include jaundice (yellowing of the skin or whites of the eyes), dark urine, pale stools, swelling of the abdomen (ascites), and easy bruising. The NHS advises that jaundice and these associated features require prompt medical assessment, as they indicate significant liver impairment.

It is worth emphasising that many people with fatty liver disease remain entirely asymptomatic for years. The absence of symptoms does not mean the condition is not progressing, which is why regular monitoring through a GP is important for those with known risk factors such as obesity, type 2 diabetes, or metabolic syndrome.

Why Does Fat Accumulation in the Liver Trigger Digestive Symptoms?

Fat-laden liver cells may impair bile production and metabolic processing, while liver inflammation releases cytokines that cause nausea; hepatomegaly can also physically compress the stomach.

Fat accumulation in the liver may contribute to digestive symptoms through several mechanisms, though the precise relationship between liver changes and gastrointestinal symptoms remains an active area of investigation and causality is not always straightforward.

One proposed mechanism involves the liver's role in bile production and regulation. When liver cells become laden with fat, their normal metabolic functions may be disrupted, potentially affecting the digestive process and contributing to symptoms such as nausea, bloating and discomfort after eating. It is important to note, however, that simple steatosis (fat accumulation without inflammation) is not inherently cholestatic, and impaired bile flow is more characteristic of advanced or complicated disease.

The liver also plays a key role in processing hormones, toxins and metabolic byproducts. When this processing is compromised, circulating levels of certain substances may rise, possibly contributing to a general feeling of nausea or malaise. Additionally, an enlarged liver (hepatomegaly), which can occur as fat accumulates, may exert physical pressure on the stomach and surrounding organs, potentially reducing gastric capacity and causing early satiety or discomfort, though this is more likely in significant hepatomegaly.

Inflammation is another important mechanism. In MASH, the liver is not only fatty but actively inflamed. This inflammatory state may trigger systemic effects, including nausea, through the release of inflammatory mediators such as cytokines. Research published in journals including Gut and the Journal of Hepatology has explored these pathways, though specific findings vary and the field continues to evolve.

Finally, fatty liver disease frequently coexists with other conditions, such as GORD, irritable bowel syndrome (IBS) and gallstone disease, all of which independently cause nausea and digestive upset. Disentangling which condition is responsible for a given symptom often requires careful clinical assessment.

When should I see a GP about nausea and possible liver problems?

See a GP if nausea persists beyond two weeks alongside upper abdominal pain, fatigue or changes in skin, eye or urine colour; call 999 for sudden severe pain, vomiting blood or rapid jaundice with confusion.

You should see a GP if nausea persists for more than two weeks without a clear explanation, particularly if it is accompanied by upper right abdominal pain, unexplained fatigue, or any change in the colour of your skin, eyes, urine or stools. These combinations of symptoms warrant investigation to exclude liver disease and other serious conditions.

Seek urgent medical attention by calling 999 or going to A&E if you experience:

• Sudden, severe abdominal pain that does not settle

• Vomiting blood or passing black, tarry stools

• Jaundice developing rapidly, especially alongside confusion or drowsiness

• Significant abdominal swelling that appears quickly

The NHS advises that rapidly developing jaundice with confusion is a medical emergency. For symptoms that are concerning but not immediately life-threatening, contact NHS 111 for guidance on how quickly you need to be seen. For persistent but non-urgent symptoms, a routine GP appointment is the appropriate first step.

Your GP will take a full history, including questions about alcohol intake, diet, weight history, any medications or supplements you take (including over-the-counter and herbal products, as some can cause liver inflammation), and family history of liver disease. If you are concerned that a medicine may be affecting your liver, do not stop taking a prescribed medicine without first seeking medical advice. This information, combined with a physical examination and blood tests, will guide whether further investigation is needed. Early identification of fatty liver disease offers the best opportunity to prevent progression to more serious liver conditions, so it is always better to raise concerns sooner rather than later.

How Is Fatty Liver Diagnosed and Managed on the NHS?

Diagnosis uses liver function tests, FIB-4 or NAFLD fibrosis score, and ultrasound per NICE NG49; management focuses on weight loss, metabolic control and alcohol reduction as no UK-licensed specific treatment exists.

Fatty liver disease is typically diagnosed on the NHS through a combination of blood tests, imaging and, in some cases, liver biopsy. Initial investigations usually include liver function tests (LFTs), which measure enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Elevated levels may suggest liver inflammation, though normal results do not exclude fatty liver disease entirely.

NICE guidance (NG49) recommends a structured approach to fibrosis risk stratification in primary care. A validated scoring tool such as the FIB-4 index or the NAFLD fibrosis score (NFS) is used as a first-line assessment to identify those at low or higher risk of significant fibrosis. Where the result is indeterminate or suggests higher risk, an enhanced liver fibrosis (ELF) blood test may be used as a second-line assessment, as supported by NICE guidance (DG34).^[3] Those with evidence of significant fibrosis or cirrhosis should be referred to a hepatology or gastroenterology specialist.

Ultrasound scanning of the abdomen is the most commonly used imaging tool in primary care and can detect increased echogenicity consistent with fat deposition. More advanced non-invasive tests, such as FibroScan (transient elastography), can assess liver stiffness and estimate the degree of fibrosis without the need for biopsy.^[4]

Management on the NHS is primarily focused on addressing the underlying causes. At the time of writing, no medicine is specifically licensed in the UK for the treatment of MASLD or NAFLD as a primary indication, though this is an evolving area and patients should ask their specialist for the most current information.^[5][6] Treatment therefore centres on:

• Weight management, with NICE (NG49) supporting a target of at least 5 to 10 per cent body weight reduction to improve liver histology^[2]

• Control of associated conditions, including type 2 diabetes, high blood pressure and raised cholesterol

• Alcohol reduction or abstinence, even in non-alcohol-related fatty liver disease, as alcohol can accelerate progression

• Regular monitoring of liver function and metabolic parameters

Referral to a specialist liver clinic is recommended for those with evidence of significant fibrosis or cirrhosis.

Can lifestyle changes ease nausea and improve liver health?

Yes, sustained weight loss of 7 to 10 per cent, a Mediterranean-style diet, alcohol reduction and regular physical activity can reduce liver fat, inflammation and associated nausea.

Lifestyle changes are the most effective intervention currently available for fatty liver disease and can meaningfully reduce both liver fat and associated symptoms, including nausea. Evidence, including data from Vilar-Gomez et al. (Hepatology, 2015) and reviewed within NICE NG49, consistently shows that sustained weight loss of 7 to 10 per cent of body weight is associated with reductions in liver inflammation and, in some cases, improvement in early fibrosis.

Dietary adjustments that support liver health include:

• Reducing intake of ultra-processed foods, refined carbohydrates and added sugars, which contribute to hepatic fat accumulation

• Increasing consumption of vegetables, wholegrains, legumes and oily fish, consistent with a Mediterranean-style dietary pattern, which has a strong evidence base for liver benefit and is supported by guidance from bodies including the European Association for the Study of the Liver (EASL)^[11]

• Limiting or avoiding alcohol, regardless of whether the fatty liver is alcohol-related

• Eating smaller, more frequent meals if nausea is a prominent symptom, as large meals can worsen upper abdominal discomfort

Regular physical activity is equally important. Both aerobic exercise and resistance training have been shown to reduce liver fat independently of weight loss.^[8] The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[9][10]

For people whose weight is significantly affecting their liver health, structured weight management support is available through NHS services, and in some cases a GP or specialist may discuss whether pharmacological support for weight management is appropriate. Any medicines used in this context are licensed for weight management, not specifically for MASLD, and will have their own contraindications and potential side effects. Where such a conversation takes place, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, as one of several routes a clinician might consider alongside NHS pathways.

If you experience any suspected side effects from medicines or supplements, these can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Nausea often improves as liver health responds to these changes, though progress should be monitored regularly with your GP.

Scientific References

1. Non-alcoholic fatty liver disease (NAFLD).
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
3. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655) – The diagnostic tests.
4. FibroScan for assessing liver fibrosis and cirrhosis (HTG682) – Consultation document.
5. Draft scope post-referral (GID-TA11477) – MASLD/MASH medicines.
6. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
7. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis (Vilar-Gomez et al., 2015).
8. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss (Hallsworth et al., 2011).
9. Physical activity guidelines: UK Chief Medical Officers' report.
10. Physical activity guidelines for adults aged 19 to 64.
11. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
12. Understanding the evolving nomenclature of steatotic liver disease (Brennan et al., 2024).
13. Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications (multi-society Delphi consensus summary).
14. Non-invasive tests for diagnosing NAFLD in adults – NICE research recommendation (NG49).
15. Identification and Characterization of Nonalcoholic Fatty Liver Disease (Younossi et al., 2019).
16. Advances in quantitative ultrasound for metabolic dysfunction-associated steatotic liver disease diagnosis.

Frequently Asked Questions